-
2024-519260-41-00
6
2020-07-15
Hormonal contraception
-
2024-512528-13-00
1
2020-05-27
Multiple System Atrophy
-
2022-501454-11-00
5
2020-02-05
standard risk ALK-positive anaplastic large cell lymphoma (ALCL)
-
2023-508926-91-00
5
2019-12-05
Stage IV childhood renal tumour with pulmonary +/- non-pulmonary
metas
-
2023-508101-24-00
5
2019-08-01
Lymphoblastic lymphoma
-
2024-512444-29-00
5
2019-05-07
patients who will undergo kidney, liver or kidney-pancreatic
transplan
-
2022-501254-10-00
5
2018-08-24
Advanced tumors
-
2024-516110-38-00
5
2018-03-06
Hepatoblastoma and Hepatocellular Carcinoma
-
2023-509318-13-00
6
2018-01-15
Multiple indications
-
2024-513637-20-00
4
2017-03-24
Locally Advanced/Metastatic Squamous Cell Carcinoma of the Skin
-
2024-512222-28-00
10
2015-06-02
Newly diagnosed with an intracranial or spinal ependymoma (all WHO gra
-
2024-516078-31-00
10
2015-05-05
Recurrent and Primary Refractory Ewing Sarcoma
-
2024-512657-24-00
10
2014-03-27
Acute Lymphoblastic Leukaemia
-
2024-515626-92-00
4
2013-10-18
recurrent/progressive medulloblastoma, ependymoma and atypical teratoi
-
2023-505829-14-00
5
2026-06-02
First recurrence glioblastoma
-
2024-520155-24-00
4
2025-10-16
Metastatic castration resistant prostate cancer (mCRPC)
-
2025-520809-12-00
10
2025-10-16
Diabetic Macular Edema
-
2024-519282-22-00
5
2025-07-09
Chronic Hepatitis D Virus (HDV) Infection
-
2024-512504-19-00
1
2025-05-28
solid tumors
-
2024-516814-39-00
5
2025-05-20
Chronic rhinosinusitis with nasal polyps
-
2024-513968-25-00
5
2025-04-28
Metastatic castration-resistant prostate cancer (mCRPC)
-
2022-501489-24-00
5
2025-03-28
First-line treatment of adult subjects with high-risk large B-cell lym
-
2024-511253-21-00
3
2025-02-28
Thoracic tumors with homozygous MTAP-deletion
-
2024-510944-30-00
10
2024-11-22
Diabetic Macular Edema